Bingchuan Wei

Bingchuan Wei

Auto-generated profile, based on publicly available information

Bingchuan Wei

Synthetic Molecule Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2017 in mAbs
Verified
Journal Article
Closed access
BWBingchuan Wei
Bingchuan Wei
KBKelsey Berning
Kelsey Berning
CQCynthia Quan
Cynthia Quan
YZYonghua Taylor Zhang
Yonghua Taylor Zhang
Glycation is an important protein modification that could potentially affect bioactivity and molecular stability, and glycation of therapeutic proteins such as monoclonal antibodies should be well characterized. Glycated protein could undergo further degradation into advance glycation end (AGE) products. Here, we review the root cause of glycation during the manufacturing, storage and in vivo circulation of therapeutic antibodies, and the current analytical methods used to detect and characterize glycation and AGEs, including boronate affinity chromatography, charge-based methods, liquid chromatography-mass spectrometry and colorimetric assay. The biological effects of therapeutic protein glycation and AGEs, which ranged from no affect to loss of activity, are also discussed.

18 June 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BWBingchuan Wei
Bingchuan Wei
BRBenjamin J. Rogers
Benjamin J. Rogers
MWMary J. Wirth
Mary J. Wirth

20 November 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
BWBingchuan Wei
Bingchuan Wei
GHGuanghui Han
Guanghui Han
JTJia Tang
Jia Tang
WSWendy Sandoval
Wendy Sandoval
YZYonghua Taylor Zhang
Yonghua Taylor Zhang

1 January 2021 in mAbs
Verified
Journal Article
Open access
BWBingchuan Wei
Bingchuan Wei
XGXuan Gao
Xuan Gao
LCLance Janssen Cadang
Lance Janssen Cadang
SISaeed Izadi
Saeed Izadi
PLPeilu Liu
Peilu Liu
GJGuoying Jiang
Guoying Jiang
Fc galactosylation is a critical quality attribute for anti-tumor recombinant immunoglobulin G (IgG)-based monoclonal antibody (mAb) therapeutics with complement-dependent cytotoxicity (CDC) as the mechanism of action. Although the correlation between galactosylation and CDC has been known, the underlying structure–function relationship is unclear. Heterogeneity of the Fc N-glycosylation produced by Chinese hamster ovary (CHO) cell culture biomanufacturing process leads to variable CDC potency. Here, we derived a kinetic model of galactose transfer reaction in the Golgi apparatus and used this model to determine the correlation between differently galactosylated species from CHO cell culture process. The model was validated by a retrospective data analysis of more than 800 historical samples from small-scale and large-scale CHO cell cultures. Furthermore, using various analytical technologies, we discovered the molecular basis for Fc glycan terminal galactosylation changing the three-dimensional conformation of the Fc, which facilitates the IgG1 hexamerization, thus enhancing C1q avidity and subsequent complement activation. Our study offers insight into the formation of galactosylated species, as well as a novel three-dimensional understanding of the structure–function relationship of terminal galactose to complement activation in mAb therapeutics.

17 February 2015
Verified
Closed access
BRBenjamin A. Rogers
Benjamin A. Rogers
ZWZhen Wu
Zhen Wu
BWBingchuan Wei
Bingchuan Wei
XZXimo Zhang
Ximo Zhang
XCXiang Cao
Xiang Cao
MWMary J. Wirth
Mary J. Wirth

1 March 2020 in Journal of Chromatography A
Verified
Journal Article
Closed access
AGAlexandre Goyon
Alexandre Goyon
LDLu Dai
Lu Dai
TCTao Chen
Tao Chen
BWBingchuan Wei
Bingchuan Wei
FYFeng Yang
Feng Yang
CSCinzia Stella
Cinzia Stella